Discover a carefully selected group of innovative companies developing alternatives to traditional viral vector gene therapies. These stocks represent biotechs working on potentially safer genetic medicine technologies like siRNA and antisense oligonucleotides, handpicked by professional analysts for their pioneering approaches.
Published on July 21
Safety concerns with traditional gene therapies are triggering a major shift in the biotech industry. These companies could be perfectly positioned to capture new investment as the market seeks safer alternatives.
These pioneers are developing cutting-edge technologies that could transform genetic medicine. Many are working on platforms that could treat previously untouchable diseases without the risks of viral vectors.
While media attention has focused on viral vector setbacks, smart money is quietly shifting toward these alternative approaches. These stocks may be undervalued before the broader market fully recognizes the potential shift.
Recent safety setbacks in viral vector gene therapies have created an opportunity for companies developing alternative approaches. This collection focuses on innovators using non-viral technologies like siRNA, antisense oligonucleotides, and CRISPR that may offer safer ways to treat genetic diseases.
This is a high-growth, high-risk thematic investment in cutting-edge biotechnology. These companies are developing next-generation genetic medicines that could potentially transform treatment for many diseases, but many are still in development stages with uncertain regulatory paths.
These companies were selected for their leadership in non-viral genetic medicine approaches that may gain favor as the market reassesses viral vector risks. They represent diverse technologies and development stages, giving exposure to multiple potential breakthrough platforms in this evolving sector.
Concise interpretation of the basket's market capitalisation and investor-focused takeaways.
ALNY: $62.13B
IONS: $11.42B
CRSP: $6.58B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
+9
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
BHP Group recently posted a massive earnings beat driven by record copper profitability, allowing the miner to raise its dividend to a four-year high. This performance highlights a structural shift toward electrification metals, creating opportunities for industrial equipment suppliers and competing copper producers.
Here are a few of the assets in this group. Create an account to unlock the full list.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+203.02%
On average, analysts expect assets in this group to grow 203.02% over the next year.
12 of 17 assets in this group are rated Buy by professional analysts.
